Indications
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Composition
- Active substance
- ixazomib citrate
- International name (INN)
- ixazomib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ninlaro
- Active substance
- ixazomib citrate
- ATC code
- L01XG03
- Therapeutic area
- Multiple Myeloma
- Marketing authorisation holder
- Takeda Pharma A/S